Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. - Wikidata - awgldk - TriplyDB

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

http://www.wikidata.org/entity/Q47254808

about

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Rituximab: mechanism of action Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis In vivo monitoring of natural killer cell trafficking during tumor immunotherapy Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies Understanding of molecular mechanisms in natural killer cell therapy Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells.Antigenic modulation and rituximab resistance.Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples FCGR3A polymorphism story: a new piece of the puzzle.FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia.A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma Natural killer cell mediated cytotoxic responses in the Tasmanian devil A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.Selection and characterization of cell binding and internalizing phage antibodies.Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease Engineered antibody Fc variants with enhanced effector function.Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals.A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity.The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases.Cancer immunotherapy comes of age Building better monoclonal antibody-based therapeutics.Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

P2860

Q21131216-6904EEC0-7AA3-496E-B834-5E3E35FFDA57 Q24607358-E2356561-0E77-4F9D-83F7-8495398A5E5A Q26766718-045DB9DB-B402-4485-A39F-151B8E9953FD Q26849243-B625EB6F-9545-430E-BEA8-E8755978F0F6 Q26852081-AF82B0EC-A2DB-42DB-9EDE-10AB5CD4A878 Q27011245-375D6885-C4F4-4072-9C65-325F1F388C88 Q28069362-640B305E-CE1B-4B78-8769-D6B2DB7FCA75 Q28086976-A531737A-5438-4F82-B4EE-F15AE166E502 Q30398870-0E94DB24-12B4-48F7-8313-0BFE32B590FE Q30432874-B0803D39-C050-4A9F-928E-B64627A97F45 Q30439017-0C530341-E227-4286-8BBD-A6C860E49282 Q30498394-47240D65-724C-4BE8-90FA-63A4B5073141 Q33347589-4E90D8CB-827C-4908-BA67-94F75FEB6D04 Q33403638-050CE601-9176-4BBC-99B8-5A384267CEDC Q33410392-A68258A2-0E3D-410F-8753-6C63F8C9592D Q33599174-92EFAA45-ECB2-4BB6-B546-E2B2397F6456 Q33944427-F5D18B80-121A-43F7-ABFA-3633777FBE4B Q34007430-1D137586-2FB7-4731-B6F6-E927B8FD9B89 Q34034657-2B01F143-805C-4CD1-A605-F0BEF40C77AF Q34065271-AC41C675-CF0D-4758-96A7-9D74C4713229 Q34076526-4E340C20-B9E5-4A33-8946-5D57FCD66DDE Q34194706-A1904557-B2E2-4A92-8132-436EF5E85723 Q34223872-A671D51F-EE27-4DAB-AA8A-7EFCF99E18FD Q34280931-44C12C07-77C8-4221-B2C6-5967ECDB3E91 Q34307792-AA36A6BD-78D5-41B6-8613-B5ECC26A7F2D Q34424958-A09BF07B-DF09-4F5F-A9B8-6CAB23E3F104 Q34574834-1ED3973C-D310-44CE-92F8-736375DD17C6 Q34598149-22ECCB01-FCEC-4F2F-8ABB-4D7BDD593AD6 Q34869927-2B9C24EA-8CA9-4993-973B-B019ADE0B6D4 Q34989602-C3A5E425-BBE0-4F94-99BD-5B57AB3FD5DB Q35031732-C1DCAADD-2C90-4ADF-BF80-4B0105E43D5D Q35037803-EAE49059-4420-410C-9AED-9428B3A44450 Q35218515-272F6112-8312-43F0-9456-D1E0F8E60CA0 Q35230227-EAA3D8A0-6F2D-409C-85A2-CA4EF907F73E Q35232342-FFD8DC3C-6D03-4015-B48C-78BE9EE4E64D Q35525404-591AC2F8-EC6A-4567-9293-C5D2D625B058 Q35635268-9C991986-49AD-48E8-9227-52117E4321B1 Q35666338-A1DF02C9-1ECC-4EC3-94F1-61E63C9D3141 Q35817552-5A935BCC-6E12-4B55-B70C-711FD1BE270A Q36007647-F329B13D-2BC1-48BE-9EE8-51FB5237DA94

P2860

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

http://www.wikidata.org/entity/Q47254808

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Rituximab-dependent cytotoxici ...... entration-effect relationship.

@en

Rituximab-dependent cytotoxici ...... entration-effect relationship.

@nl

type

label

Rituximab-dependent cytotoxici ...... entration-effect relationship.

@en

Rituximab-dependent cytotoxici ...... entration-effect relationship.

@nl

prefLabel

Rituximab-dependent cytotoxici ...... entration-effect relationship.

@en

Rituximab-dependent cytotoxici ...... entration-effect relationship.

@nl

P1433

Q47254808-3572CFA1-EC72-44B1-9F22-0C79E01E23A9

P1476

Q47254808-4AABF8C8-D0E8-4589-A6AE-2E80C539E971

P2093

Q47254808-0DD58CEB-513E-41D7-BFD9-22D099E69E2A

Q47254808-312B45D7-4631-47FC-8F36-460CDFA30904

Q47254808-A28AD994-1E47-48DF-B218-C8E3D35F49A9

Q47254808-AAC1D865-3B3E-4A09-960F-64562100FEFF

Q47254808-B0F86F4D-6AAC-4BAF-BD3A-F0B9272A0B70

Q47254808-B4F514B7-94EB-45C0-9EB5-D245199C7380

P304

Q47254808-68AB7B55-985C-4EA9-B4C8-DF7A10ADFF4B

P31

Q47254808-7604A35B-A0F4-41EB-8C38-3EF2CA49657F

P356

Q47254808-A83B8A45-575F-4ECF-8065-91D01B79BEBA

P407

Q47254808-1070D2F4-197F-46A9-96DB-8B31FE4B4CDD

P433

Q47254808-2E0602DC-E783-4E28-8444-4CE55D4AFC7A

P478

Q47254808-0515EE54-B434-442B-B97E-3BC18FBDAD91

P50

Q47254808-956FAEFE-7351-473A-A54B-F01498D488DA

Q47254808-9E641689-80BB-4B82-A8DD-9ED8B3FC94DF

P577

Q47254808-DEB443CC-5260-47DC-8F60-A91CE979CC89

P698

Q47254808-200B67FE-61B2-4B7C-B3F3-92B3EA27E05C

P921

Q47254808-5F1E8DF4-A401-490E-99F3-6B71ECDFA38D

P356

0008-5472.CAN-03-2862

P1433

Cancer Research

P1476

Rituximab-dependent cytotoxici ...... centration-effect relationship

@en

P2093

Gilles Thibault

http://www.w3.org/2001/XMLSchema#string

Hervé Watier

http://www.w3.org/2001/XMLSchema#string

Philippe Colombat

http://www.w3.org/2001/XMLSchema#string

Pierre Bardos

http://www.w3.org/2001/XMLSchema#string

Sophie Tartas

http://www.w3.org/2001/XMLSchema#string

Sébastien Dall'Ozzo

http://www.w3.org/2001/XMLSchema#string

P304

4664-4669

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-03-2862

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Guillaume Cartron

Gilles Paintaud

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15231679

http://www.w3.org/2001/XMLSchema#string

P921